Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body dysmorphic disorder of at least moderate severity, non-delusional subtype, for \>6 months~* History of intolerance of, or nonresponse to, a prior adequate trial of a serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)~* Currently in psychotherapy (other than cognitive behavioral therapy (CBT) for body dysmorphic disorder~Exclusion Criteria:~* Current major depressive disorder of greater than moderate severity~* Other significant psychiatric or medical comorbidity or conditions that could interfere with safety of participation or interpretation of outcomes~* Use of: investigational medication within 3 months of baseline; depot antipsychotic within 6 months of baseline; serotonergic medication within 2 weeks of baseline (6 weeks for fluoxetine).~* Females who are pregnant, breastfeeding, or sexually active and not willing to use adequate contraception~* Enrollment in any investigational drug or device study in past 30 days~* Prior adverse effects from psilocybin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): A single dose of Psilocybin 25mg p.o.

Based on this trial design, predict the completion outcome and termination type (if applicable).